Actively Recruiting
Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)
Led by Shanghai Bluesail Boyuan Medical Technology Co., Ltd. · Updated on 2025-05-16
204
Participants Needed
1
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
* Clinical Trial Summary * Trial Title:\*\* CREATE Trial: Safety and Efficacy of IVL for Carotid Calcified Lesions * Sponsor:\*\* Shanghai Bluesail Boyuan Medical Technology Co., Ltd. * Clinical Trial Leader:\*\* Beijing Anzhen Hospital * Coordinating Investigator:\*\* Prof. Huo Xiaochuan * Study Purpose This trial assesses a new device-a single-use neurovascular intravascular shockwave catheter and therapy device-for treating calcified blockages in the carotid artery. It uses sound waves to break up calcium deposits, facilitating stent placement and blood flow restoration. * Eligibility * Adults aged 18-80 with severe carotid artery narrowing (≥50% symptomatic or ≥70% asymptomatic) due to calcium buildup. * Patients who failed standard balloon dilation. * Exclusions include pregnancy, recent strokes/heart attacks, uncontrolled hypertension, or other high-risk conditions. * Study Design * \*\*Type:\*\* Prospective, multicenter, single-arm trial. * \*\*Sample Size:\*\* 204 patients across multiple hospitals. * \*\*Duration:\*\* 1-month follow-up post-procedure. * Procedures 1. \*\*Pre-treatment:\*\* Imaging (CT angiography, ultrasound) to confirm eligibility. 2. \*\*Procedure:\*\* Shockwave catheter breaks up calcium, followed by stent placement. 3. \*\*Follow-up:\*\* Assessments at 7 days (or discharge) and 1 month post-procedure. * Benefits and Risks * \*\*Benefits:\*\* Improved stent placement success, reduced risk of complications, minimally invasive with shorter recovery time. * \*\*Risks:\*\* Bleeding, infection, vessel damage, stroke, heart attack, device malfunction. Risks are closely monitored with emergency protocols. * Patient Protections * Ethics committee approval and strict safety guidelines. * Voluntary participation with the option to withdraw anytime. * Free treatment and compensation for trial-related injuries. * For Healthcare Providers * \*\*Innovation:\*\* Adapts coronary lithotripsy technology for carotid use. * \*\*Evidence:\*\* Supported by preclinical data and a pilot study (100% success rate in 5 patients). * \*\*Endpoints:\*\* Primary: Stent success (residual stenosis \<30%) and 30-day major adverse events. Secondary: Device success rate, repeat procedures, long-term outcomes. * Contact Information For questions, contact: \*\*Ms. Zhang Yanjiao\*\* Email: yanjiao.zhang@jwmsgrp.com
CONDITIONS
Official Title
Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years, any gender
- Severe carotid artery narrowing confirmed by CT angiography: symptomatic 50% or asymptomatic 70% with over 50% calcification around the artery
- Carotid stenosis confirmed by intraoperative angiography: symptomatic 50% or asymptomatic 70%
- Modified Rankin Scale score of 2 or less before enrollment
- Planned for carotid artery stenting after failing conventional balloon dilation
- Ability to understand the trial purpose, provide informed consent, and comply with follow-up
You will not qualify if you...
- Blockage caused by non-atherosclerotic disease
- Complete blockage of the target lesion or opposite carotid artery
- Severe disability from cerebral infarction
- Large acute or subacute blood clots near the lesion, arteriovenous malformations, or aneurysms
- Tortuous vessels preventing stent placement
- Severe narrowing in other brain vessels
- Need for additional surgery during the trial
- Severe narrowing or blockage in vessels near the target lesion
- Heart attack or large stroke within 2 weeks before screening
- Brain bleeding within 3 months before screening
- Unstable or high-risk plaques prone to rupture or clotting
- Uncontrolled high blood pressure (systolic 180 mmHg or diastolic 110 mmHg)
- Low platelet count, severe liver or kidney impairment, or advanced heart failure
- Blood clotting disorder or contraindication to heparin or antiplatelet drugs
- Active infections
- Unable to use cerebral protection devices
- Allergy to device components or contrast agents (except rash)
- Life expectancy less than 1 year
- Pregnant or breastfeeding
- Currently enrolled in another drug or device trial
- Other conditions the investigator considers unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing An Zhen Hospital of the Capital University of Medical Sciences
Beijing, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here